Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma

与替代皮质类固醇方案相比，地塞米松作为复发/难治性大B细胞淋巴瘤患者接受格洛菲单抗治疗前的预用药，可降低细胞因子释放综合征的发生频率和严重程度。